Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;30(4):355-361.
doi: 10.1111/jvh.13798. Epub 2023 Jan 11.

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Marilyne Debette-Gratien  1 , Sandrine François  1 , Catherine Chevalier  2 , Sophie Alain  3 , Paul Carrier  1 , Céline Rigaud  1 , Bruno Abraham  4 , Anne-Laure Burgevin  5 , Laurent Courat  6   7 , Bernard Debenes  8 , Joseph Koffi  9 , Elisabeth Caux-Nussbaum  10 , Juliette Zattoni-Leroy  2   11 , Gaëlle Feuillet-Sow  12 , Quentin Dumont  13 , Philippe Nubukpo  2 , Véronique Loustaud-Ratti  1
Affiliations

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Marilyne Debette-Gratien et al. J Viral Hepat. 2023 Apr.

Abstract

According to the French recommendations, the elimination of the hepatitis C virus by 2025 could be a realistic public health goal. Screening policies are being intensified, and access to treatment is promoted for patients who escape the usual care pathway. The 'Scanvir' program is an original strategy based on dedicated screening days, as part of the 'test, treat and cure HCV' event in addiction care centers in a French region, during which innovative screening technologies (RDTs, FibroScan® and point-of-care HCV RNA testing) are brought on site and access to a multidisciplinary team is offered. A total of 392 patients attended the 67 regional Scanvir sessions: 31.6% were HCV Ab-positive and 66% of them were HCV RNA-positive. Treatment was initiated in 79.3% of the patients. RDTs were accepted by 62% of the PWIDs (including those who already knew their status) and FibroScan® by 99.5% of the patients. 80% of the viremic patients started their treatment on site and are now cured or still under treatment. Advanced fibrosis evaluated by FibroScan® (LSM > 8 KPa) was suspected in 13.4% and 14.1% of the global and the HCV population, respectively. Scanvir is an efficient strategy for HCV elimination based on dedicated days aimed at increasing cost-effectiveness and offering a multidisciplinary service while saving human care resources. It is an exportable strategy that also offers comprehensive screening of associated chronic liver diseases via the elastometry device and interviews.

Trial registration: ClinicalTrials.gov NCT05361603.

Keywords: HCV elimination; HCV screening; drug users; liver elastometry; point-of-care HCV RNA assay.

PubMed Disclaimer

References

REFERENCES

    1. Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40(3):522-529. doi:10.1111/liv.14324
    1. Tran A, Shili-Masmoudi S, Moga L, et al. Non-invasive diagnosis and follow-up of chronic infection with hepatitis C virus. Clin Res Hepatol Gastroenterol. 2021;46(1):101771. doi:10.1016/j.clinre.2021.101771
    1. Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20(5):436-446. doi:10.1038/s41435-019-0066-z
    1. Brouard C, Pillonel J, Boussac M, et al. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long. BMC Infect. Dis. 2020;20(1):759. doi:10.1186/s12879-020-05478-6
    1. Brouard C, Saboni L, Gautier A, et al. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC Infect. Dis. 2019;19(1):896. doi:10.1186/s12879-019-4493-2

Publication types

Associated data